Abstract
A boronic acid moiety was found to be a critical pharmacophore for enhanced in vitro potency against wild-type hepatitis C replicons and known clinical polymorphic and resistant HCV mutant replicons. The synthesis, optimization, and structure-activity relationships associated with inhibition of HCV replication in a subgenomic replication system for a series of non-nucleoside boron-containing HCV RNA-dependent RNA polymerase (NS5B) inhibitors are described. A summary of the discovery of 3 (GSK5852), a molecule which entered clinical trials in subjects infected with HCV in 2011, is included.
MeSH terms
-
Antiviral Agents / chemistry
-
Antiviral Agents / pharmacology*
-
Boronic Acids / chemistry*
-
Drug Discovery
-
Drug Resistance, Viral / genetics
-
Enzyme Inhibitors / pharmacology*
-
Hepacivirus / drug effects*
-
Hepacivirus / enzymology
-
Hepacivirus / genetics
-
Magnetic Resonance Spectroscopy
-
Models, Molecular
-
RNA-Dependent RNA Polymerase / antagonists & inhibitors*
-
Structure-Activity Relationship
-
Viral Nonstructural Proteins / antagonists & inhibitors
Substances
-
Antiviral Agents
-
Boronic Acids
-
Enzyme Inhibitors
-
Viral Nonstructural Proteins
-
NS-5 protein, hepatitis C virus
-
RNA-Dependent RNA Polymerase